Logo image of JUNS

JUPITER NEUROSCIENCES INC (JUNS) Stock Overview

NASDAQ:JUNS - US48208B2034 - Common Stock

1.46 USD
-0.02 (-1.35%)
Last: 8/27/2025, 3:27:27 PM

JUNS Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap48.33M
Shares33.10M
Float14.00M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.15
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-03 2024-12-03
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


JUNS short term performance overview.The bars show the price performance of JUNS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

JUNS long term performance overview.The bars show the price performance of JUNS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of JUNS is 1.46 USD. In the past month the price increased by 4.96%.

JUPITER NEUROSCIENCES INC / JUNS Daily stock chart

JUNS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.31 692.58B
JNJ JOHNSON & JOHNSON 17.68 425.87B
NVO NOVO-NORDISK A/S-SPONS ADR 14.45 250.41B
AZN ASTRAZENECA PLC-SPONS ADR 18 247.74B
NVS NOVARTIS AG-SPONSORED ADR 14.34 245.73B
MRK MERCK & CO. INC. 10.93 210.29B
PFE PFIZER INC 7.4 142.62B
SNY SANOFI-ADR 11.36 122.51B
BMY BRISTOL-MYERS SQUIBB CO 7.07 96.87B
GSK GSK PLC-SPON ADR 8.84 80.57B
ZTS ZOETIS INC 24.96 68.81B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.53 46.93B

About JUNS

Company Profile

JUNS logo image Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. The company has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Company Info

JUPITER NEUROSCIENCES INC

1001 North US HWY 1, Suite 504

Palm Beach Gardens FLORIDA US

Employees: 4

JUNS Company Website

JUNS Investor Relations

Phone: 15614066154

JUPITER NEUROSCIENCES INC / JUNS FAQ

What is the stock price of JUPITER NEUROSCIENCES INC today?

The current stock price of JUNS is 1.46 USD. The price decreased by -1.35% in the last trading session.


What is the ticker symbol for JUPITER NEUROSCIENCES INC stock?

The exchange symbol of JUPITER NEUROSCIENCES INC is JUNS and it is listed on the Nasdaq exchange.


On which exchange is JUNS stock listed?

JUNS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for JUPITER NEUROSCIENCES INC stock?

7 analysts have analysed JUNS and the average price target is 30.6 USD. This implies a price increase of 1995.89% is expected in the next year compared to the current price of 1.46. Check the JUPITER NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is JUPITER NEUROSCIENCES INC worth?

JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 48.33M USD. This makes JUNS a Nano Cap stock.


How many employees does JUPITER NEUROSCIENCES INC have?

JUPITER NEUROSCIENCES INC (JUNS) currently has 4 employees.


What are the support and resistance levels for JUPITER NEUROSCIENCES INC (JUNS) stock?

JUPITER NEUROSCIENCES INC (JUNS) has a support level at 1.39 and a resistance level at 1.61. Check the full technical report for a detailed analysis of JUNS support and resistance levels.


Should I buy JUPITER NEUROSCIENCES INC (JUNS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does JUPITER NEUROSCIENCES INC (JUNS) stock pay dividends?

JUNS does not pay a dividend.


What is the Price/Earnings (PE) ratio of JUPITER NEUROSCIENCES INC (JUNS)?

JUPITER NEUROSCIENCES INC (JUNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).


What is the Short Interest ratio of JUPITER NEUROSCIENCES INC (JUNS) stock?

The outstanding short interest for JUPITER NEUROSCIENCES INC (JUNS) is 0.31% of its float. Check the ownership tab for more information on the JUNS short interest.


JUNS Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to JUNS.


Chartmill TA Rating
Chartmill Setup Rating

JUNS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to JUNS. While JUNS seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

JUNS Financial Highlights

Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.15.


Industry RankSector Rank
PM (TTM) N/A
ROA -77.13%
ROE -114.66%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%-383%
Sales Q2Q%N/A
EPS 1Y (TTM)0%
Revenue 1Y (TTM)-100%

JUNS Forecast & Estimates

7 analysts have analysed JUNS and the average price target is 30.6 USD. This implies a price increase of 1995.89% is expected in the next year compared to the current price of 1.46.


Analysts
Analysts82.86
Price Target30.6 (1995.89%)
EPS Next Y66%
Revenue Next YearN/A

JUNS Ownership

Ownership
Inst Owners1.17%
Ins Owners49.23%
Short Float %0.31%
Short Ratio0.07